Pericardial Mesothelioma: Symptoms, Diagnosis, Treatment and Prognosis

Pericardial Mesothelioma at a Glance

The rarity estimates and asbestos qualification are supported by systematic review and national registry evidence.

What Is Pericardial Mesothelioma?

The pericardium is a sac-like membrane surrounding the heart. Its layers are separated by a small amount of fluid that allows the heart to move normally as it beats.

Primary pericardial mesothelioma develops from mesothelial cells of this membrane.

The term primary is important. Cancers that begin elsewhere in the body can spread to the pericardium, and metastatic involvement of the pericardium is far more common than a cancer that originates there.

Primary pericardial mesothelioma may appear as a localized mass, but many reported tumors show diffuse involvement of the pericardium. Disease can also extend into nearby mediastinal structures, the myocardium, or major vessels.

Because this disease is exceptionally rare, many clinicians may never encounter a case in their careers.

How Rare Is Pericardial Mesothelioma?

Primary pericardial mesothelioma is among the rarest forms of mesothelioma.

A systematic review estimated that approximately 0.7% of mesotheliomas originate in the pericardium.

Population-level evidence also demonstrates how uncommon it is. The Italian National Mesothelioma Registry identified only 58 pericardial cases between 1993 and 2015, with annual standardized incidence rates of approximately 0.049 cases per million men and 0.023 cases per million women.

A contemporary review identified 103 published cases from 2000 through 2016, underscoring how limited the evidence base remains even when cases from many years and locations are combined.

A 2026 case report and literature review likewise describes primary pericardial mesothelioma as exceptionally rare, with diagnosis often difficult and disease-specific evidence still limited.

This rarity means treatment recommendations lack the volume and quality of evidence available for pleural mesothelioma or more common cancers.

What Causes Pericardial Mesothelioma?

The cause of primary pericardial mesothelioma remains incompletely understood.

Asbestos Exposure

The relationship between asbestos and primary pericardial mesothelioma is much less established than the relationship between asbestos and pleural mesothelioma.

Older case literature frequently failed to demonstrate a convincing exposure pattern. For example, one historical review identified recognized asbestos exposure in only 3 of 14 cases with available exposure information.

A 2020 national registry-based case-control study provides additional context; it supports an association with occupational asbestos exposure but does not by itself establish causation.

A case-control analysis based on the Italian National Mesothelioma Registry found that occupational asbestos exposure was associated with pericardial mesothelioma, with an odds ratio of 3.68 and a 95% confidence interval of 1.85–7.31. The study included only 58 pericardial cases because the disease itself is extremely rare.

A patient does not need a recognized history of asbestos exposure for clinicians to consider the diagnosis. Our asbestos exposure guide covers this topic more broadly across mesothelioma types.

Does Smoking Cause Pericardial Mesothelioma?

Smoking is not considered an established cause of mesothelioma.

While smoking is a significant risk factor for other cancers and cardiovascular diseases, it should not be used to determine the likelihood of pericardial mesothelioma.

Genetics and Germline Testing

Genetic susceptibility is increasingly recognized across mesothelioma, although evidence specifically characterizing inherited risk in primary pericardial mesothelioma is extremely limited.

Current ASCO guidance recommends that all patients with mesothelioma be offered germline testing. Patients offered germline testing should also be offered pretest genetic counseling with a qualified health professional.

Testing may include BAP1 and other genes associated with inherited cancer susceptibility.

For patients with pericardial mesothelioma, these findings should be interpreted cautiously. Most genetic recommendations are based on evidence from pleural and peritoneal disease, not large pericardial cohorts.

A germline result may have implications for the patient and relatives, but it does not explain why a pericardial tumor developed or determine a specific treatment.

Symptoms of Pericardial Mesothelioma

Symptoms are often caused by pericardial fluid accumulation, pressure around the heart, or impaired cardiac filling, rather than by features specific to mesothelioma.

Reported presentations include:

• shortness of breath
• chest pain or discomfort
• fatigue
• persistent cough
• palpitations
• reduced exercise tolerance
• swelling of the legs or abdomen
• recurrent pericardial effusion
• constrictive pericarditis
• cardiac tamponade

Chest discomfort and shortness of breath are among the most frequently reported symptoms in systematic reviews.

These symptoms have many more common causes. Infection, inflammatory disease, other forms of pericarditis, heart failure, and metastatic cancer can produce similar findings.

This lack of specificity often contributes to delayed diagnosis. Our symptoms guide covers the broader range of possible signs across all mesothelioma types.

Pericardial Effusion

A pericardial effusion is an abnormal accumulation of fluid within the pericardial space.

It is one of the most important presentations associated with primary pericardial mesothelioma.

Some patients experienced recurrent fluid accumulation after drainage, with tumor diagnosis made only after repeated investigations or surgery.

Pericardial effusion itself is not evidence of mesothelioma. Many other cardiovascular, inflammatory, infectious and malignant conditions can cause an effusion.

If fluid is recurrent or unexplained, especially when imaging shows pericardial thickening, nodules, or a mass, further investigation may be warranted.

What Is Cardiac Tamponade?

When pericardial fluid accumulates rapidly or creates enough pressure to interfere with cardiac filling, cardiac tamponade can develop.

Cardiac tamponade requires immediate medical attention.

The 2025 European Society of Cardiology guidelines define tamponade as a pericardial syndrome in which an effusion impairs diastolic filling and reduces cardiac output. Treatment centers on drainage of the pericardial fluid, generally by image-guided pericardiocentesis, and drainage should not be delayed in an unstable patient.

For patients with suspected cancer, initial management focuses on relieving hemodynamic effects and stabilizing the patient. Evaluation of the underlying cause, including malignancy, follows stabilization.

Pericardial mesothelioma is a possible malignant cause of tamponade, but it is exceptionally rare.

Constrictive Pericarditis

Pericardial mesothelioma can also lead to constrictive physiology.

When the pericardium becomes thickened, infiltrated, or rigid, normal filling of the heart can be impaired.

Patients may develop:

• fatigue
• breathlessness
• swelling
• reduced exercise tolerance
• or other signs resembling heart failure

Modern ESC guidance describes constriction as impaired cardiac filling caused by abnormal pericardial restriction, while published cases demonstrate that primary pericardial mesothelioma can occasionally be the underlying cause.

Many noncancerous conditions can cause constrictive pericarditis, so this finding alone does not confirm mesothelioma.

How Pericardial Mesothelioma Is Diagnosed

There is no single symptom, blood test, or imaging study that can establish a diagnosis of primary pericardial mesothelioma.

Diagnosis generally requires a combination of:

• clinical and cardiac assessment
• imaging
• evaluation for other possible primary cancers
• and pathology

Because metastatic cancer involving the pericardium is more common than primary pericardial mesothelioma, determining the true site of origin is essential in diagnosis. Our diagnosis guide covers this process in more detail.

Echocardiography

Echocardiography is often one of the first investigations performed when clinically important pericardial disease is suspected.

It can identify:

• pericardial effusion
• impaired cardiac filling
• signs of tamponade
• some pericardial masses
• and physiologic features of constriction

Echocardiography is valuable for assessing the impact of pericardial disease on heart function. ESC guidance recommends echocardiography as a primary tool for evaluating pericardial effusion and tamponade.

An echocardiogram cannot by itself establish that abnormal pericardial tissue is mesothelioma.

CT Imaging

Contrast-enhanced CT of the chest can provide detailed information about the anatomy of the pericardium and nearby structures.

Possible findings in published pericardial-mesothelioma cases include:

• pericardial thickening
• nodular pericardial disease
• pericardial masses
• effusion
• mediastinal involvement
• lymph-node abnormalities
• extension toward nearby cardiovascular structures

CT is also useful for evaluating the lungs, pleura, and mediastinum, and for identifying whether another primary cancer may be responsible for pericardial involvement.

Imaging cannot reliably determine histology.

Cardiac MRI

Cardiac MRI provides high soft-tissue contrast and may help specialists define the relationship between abnormal pericardial tissue and the heart or nearby structures.

It can be useful when evaluating:

• myocardial involvement
• major-vessel involvement
• pericardial thickening
• local mediastinal extension
• and constrictive physiology

Systematic-review data indicate that CT and MRI are more informative than plain radiography or echocardiography for defining tumor extent and involvement of adjacent structures. Our imaging tests guide covers CT, PET, and MRI in more detail.

Imaging strategies should be tailored to each patient.

PET/CT

PET/CT may be considered in selected patients to assess metabolically active disease and look for possible disease outside the immediate pericardial region.

Its role in primary pericardial mesothelioma has not been established through large prospective studies.

Increased metabolic activity is also not specific for mesothelioma and can occur with other cancers and inflammatory conditions.

Therefore, PET/CT does not replace the need for tissue diagnosis.

Pericardial Fluid Cytology

Fluid removed during pericardiocentesis is commonly sent for cytologic examination.

Cytology is an important diagnostic test for malignant pericardial effusions overall and can identify metastatic cancer involving the pericardium. In a 2025 multi-institutional study of 309 cases with concurrent cytology and pericardial biopsy, 99 were confirmed malignant; sensitivity was 84.8% for fluid cytology and 65.7% for biopsy. Most malignancies in that study were metastatic cancers rather than primary pericardial mesothelioma.

Primary pericardial mesothelioma poses a unique diagnostic challenge.

Older PPM-focused case literature identified malignant cells in only 4 of 17 examined pericardial-fluid specimens, and negative or inconclusive cytology has repeatedly been described before the eventual tissue diagnosis.

If imaging or clinical findings remain suspicious, further investigation and adequate tissue sampling may be necessary. Our tests and biopsy guide covers these procedures in more detail.

Pericardial Biopsy

Adequate tissue may be obtained through a pericardial biopsy, surgical pericardial window, pericardiectomy, or another procedure selected according to the patient’s anatomy and clinical condition.

Tissue provides architectural information needed to distinguish mesothelioma from reactive mesothelial proliferation and from other cancers involving the pericardium.

In some cases, diagnosis was only established after surgery for recurrent effusion or constrictive disease.

Because mesothelioma pathology is complex, specialist pathology review is recommended whenever possible.

How Pathologists Confirm Pericardial Mesothelioma

Mesothelioma should not be diagnosed based on one immunohistochemical marker.

The International Mesothelioma Interest Group recommends integrating morphology with an appropriate immunohistochemical panel and the clinical-radiologic context.

Markers supporting mesothelial differentiation can include:

• calretinin
• WT1
• D2-40
• cytokeratin 5/6

Markers expected to be negative in mesothelioma and useful for excluding carcinoma can include claudin-4, CEA, EpCAM, and TTF-1, selected according to the differential diagnosis. Mesothelioma diagnosis should rely on an appropriate panel rather than any single immunohistochemical marker.

Ancillary testing involving BAP1, MTAP, or CDKN2A may sometimes contribute to the assessment of mesothelial malignancy.

However, most evidence defining the performance of these tests comes from pleural and peritoneal mesothelioma rather than large cohorts of primary pericardial disease.

No individual biomarker should be used in isolation to diagnose primary pericardial mesothelioma.

Histologic Types

The broad histologic patterns recognized in mesothelioma at other serosal sites can also occur in the pericardium.

A modern 12-patient institutional cohort included nine epithelioid and three non-epithelioid tumors, but a cohort this small cannot define the true population distribution of histologic subtypes.

Histology should be considered as part of the overall clinical assessment, not as the sole basis for treatment decisions.

Conditions That Can Resemble Pericardial Mesothelioma

Many disorders are substantially more common than primary pericardial mesothelioma.

The differential diagnosis may include:

• metastatic carcinoma involving the pericardium
• lymphoma
• primary cardiac or mediastinal tumors
• inflammatory pericarditis
• infectious pericarditis
• reactive mesothelial proliferation
• other causes of recurrent pericardial effusion

Metastatic cancers, especially those from the lung and breast, account for most malignant pericardial effusions, far exceeding cases of primary pericardial mesothelioma.

Pathology should be interpreted alongside whole-body imaging and clinical history.

Is There a Staging System for Pericardial Mesothelioma?

There is no validated AJCC Stage I–IV system specifically established for primary pericardial mesothelioma.

The pleural mesothelioma staging system should not be applied to cancers originating in the pericardium.

Instead, specialists evaluate the actual distribution of disease.

Important considerations include:

• localized versus diffuse pericardial involvement
• myocardial invasion
• involvement of major cardiovascular structures
• mediastinal extension
• lymph-node disease
• distant metastases
• technical feasibility of meaningful surgical removal

In the contemporary 103-case review, metastatic or mediastinal spread was associated with worse survival.

These characteristics provide more clinical value than assigning an unsupported numerical stage.

Treatment of Pericardial Mesothelioma

There is no universally accepted standard treatment pathway for primary pericardial mesothelioma.

Treatment decisions therefore depend on factors such as:

• cardiovascular stability
• disease distribution
• histology
• surgical feasibility
• presence of metastatic disease
• symptoms
• previous therapy
• performance status
• overall health
• patient preferences

Most available evidence comes from published cases, retrospective reviews, and small institutional series.

Major treatment decisions should, whenever possible, involve a multidisciplinary team experienced in complex pericardial disease and mesothelioma. Our treatment guide covers the full range of approaches used across mesothelioma types.

Treating Pericardial Effusion and Tamponade

When a patient develops symptomatic pericardial effusion or cardiac tamponade, immediate management of the cardiovascular issue is the priority.

Image-guided pericardiocentesis may be used to drain fluid. Surgical drainage may be necessary if percutaneous drainage is not feasible or if another procedure is clinically preferable.

For recurrent effusions with hemodynamic consequences, a pericardial window may be considered in selected circumstances.

The appropriate strategy depends on:

• hemodynamic stability
• recurrence
• anatomy
• previous procedures
• overall cancer status
• expected disease course

For patients with suspected pericardial mesothelioma, drainage or surgical procedures may also provide an opportunity to obtain diagnostic tissue.

Surgery

The role of surgery depends largely on the tumor’s extent and location.

A localized, resectable tumor presents a very different clinical scenario than diffuse disease encasing the heart or invading major vessels.

Selected patients with localized disease have undergone substantial or complete resection, and prolonged survival has occasionally been reported.

However, complete resection is often not feasible due to diffuse pericardial involvement or invasion of critical structures.

Operations may therefore involve:

• tumor resection in highly selected cases
• partial or more extensive pericardiectomy
• debulking
• a pericardial window
• procedures primarily intended to relieve constriction or recurrent effusion

The 103-case contemporary review did not show a statistically significant survival advantage for surgery alone. This does not prove surgery is ineffective, as retrospective case series are strongly influenced by disease extent and patient selection.

Surgery should not be considered automatically appropriate solely based on a diagnosis of pericardial mesothelioma.

Multimodality Treatment

Due to common local progression and recurrence, combinations of surgery, chemotherapy, and radiation have been used in selected patients.

A Memorial Sloan Kettering retrospective cohort included only 12 patients with primary pericardial mesothelioma. Median overall survival for the cohort was 25.9 months. Three patients received trimodality therapy (surgery, chemotherapy, and radiation); their observed overall survival was 70.3 months versus 8.2 months among patients who did not receive trimodality therapy.

The cohort was very small, retrospective, and highly susceptible to selection bias. Patients who received surgery and multiple treatments likely had different disease characteristics and overall health compared to those with advanced, unresectable disease.

Therefore, the study does not establish that trimodality therapy provides the same benefit for all patients with primary pericardial mesothelioma.

Systemic Chemotherapy

No chemotherapy regimen has been validated specifically for primary pericardial mesothelioma in randomized clinical trials.

Most systemic treatment practices are extrapolated from mesothelioma at other sites and from pericardial case reports.

Platinum-based chemotherapy, commonly combined with pemetrexed, is among the most frequently reported systemic approaches.

In the 2000–2016 published-case review of 103 patients, median survival was reported as 13 months among patients who received chemotherapy versus 0.5 months among those who did not, and chemotherapy remained associated with improved survival in multivariable analysis.

This comparison requires substantial caution.

The study was not randomized. Patients receiving treatment were likely healthier, may have had different disease characteristics, and had to survive long enough to begin chemotherapy.

Therefore, the finding demonstrates an association, not proof that chemotherapy leads to a specific survival benefit for individual patients.

The oncology team should individualize systemic treatment decisions.

Immunotherapy

Immunotherapy has changed treatment for some pleural mesothelioma patients, but these results cannot be directly applied to primary pericardial mesothelioma.

No dedicated randomized trials have demonstrated a survival benefit from nivolumab plus ipilimumab, pembrolizumab, or other immune-checkpoint regimens specifically in primary pericardial mesothelioma.

Published evidence is largely limited to individual case reports.

A 2021 report described a patient with primary pericardial mesothelioma treated with an immune-checkpoint inhibitor as second-line treatment.

A separate 2024 case report described a multimodality approach involving pericardial surgery followed by carboplatin, pemetrexed and pembrolizumab and then radiation therapy.

Case reports demonstrate that treatments have been used and document individual outcomes, but they cannot establish a standard of care or predict responses in other patients.

Immunotherapy for primary pericardial mesothelioma should therefore be considered an individualized specialist decision, potentially informed by:

• evidence from other mesothelioma sites
• previous treatment
• histology and other tumor characteristics
• comorbidities
• expected toxicity
• clinical-trial availability

Radiation Therapy

Radiation therapy may have a role in selected circumstances, but its optimal use in primary pericardial mesothelioma is uncertain.

Potential uses may include:

• selected postoperative multimodality treatment
• local control of unresectable disease
• palliation of a specific symptomatic site

Radiation near the heart requires careful treatment planning because the heart, lungs, esophagus, and other surrounding structures can be sensitive to radiation.

Small retrospective series have reported prolonged survivors who received radiation as one component of multimodality therapy, but those observations cannot establish a universal treatment benefit.

What Happens if the Disease Cannot Be Removed?

Unresectable disease does not mean medical care stops.

Depending on the patient’s condition and goals, management may include:

• systemic therapy
• control of recurrent pericardial effusion
• treatment of cardiovascular symptoms
• radiation for selected local problems
• clinical trials
• supportive and palliative care

Treatment goals may also change over time according to response, progression and the patient’s cardiovascular and general health.

Recurrent Pericardial Effusion

Repeated fluid accumulation can substantially affect symptoms and quality of life.

Management depends on:

• how rapidly the fluid returns
• whether cardiac filling is affected
• symptoms
• previous drainage procedures
• disease status
• overall health

Some patients may undergo additional pericardiocentesis, while others may be considered for a pericardial window or another surgical approach intended to provide more durable drainage.

ESC guidance specifically recognizes pericardial-window procedures as an option for relapsing effusion with hemodynamic compromise despite conservative management or previous percutaneous drainage.

There is no single procedure appropriate for every patient.

Supportive and Palliative Care

Supportive care should be integrated throughout treatment.

Symptoms that may require active management include:

• shortness of breath
• chest discomfort
• fatigue
• reduced appetite
• sleep disturbance
• anxiety
• limitations in daily activity

Palliative care is not synonymous with hospice or stopping cancer treatment.

Palliative-care specialists can work alongside cardiology, oncology and surgery to help manage symptoms, support decision-making and protect quality of life while anticancer treatment continues.

Clinical Trials

Clinical research is especially important for primary pericardial mesothelioma because disease-specific treatment evidence is extremely limited.

There are too few patients for most therapeutic questions to have been answered through dedicated randomized trials.

Depending on the clinical situation, specialists may investigate trials involving:

• mesothelioma
• rare cancers
• immunotherapy
• molecularly selected cancers
• novel systemic treatments

Eligibility depends on the individual protocol and must be determined by the clinical-trial team.

Evidence generated in a trial restricted to pleural mesothelioma should not automatically be presented as proof of efficacy in pericardial disease.

Pericardial Mesothelioma Prognosis

Primary pericardial mesothelioma is generally an aggressive disease, but survival statistics require careful interpretation.

In the 103-case review of reports published from 2000 through 2016, median overall survival was approximately 6 months. Metastatic or mediastinal spread was associated with worse survival. This is a historical published-case estimate, not a contemporary population-based survival estimate.

These numbers should not be interpreted as a fixed life expectancy.

The published-case literature combines patients:

• treated in different eras
• diagnosed at different stages of disease
• receiving very different treatments
• with different levels of cardiovascular compromise
• and with different possibilities for surgery

Selected contemporary patients have experienced substantially longer survival.

For example, the 12-patient Memorial Sloan Kettering cohort reported median overall survival of 25.9 months. Still, its small size and strong potential for patient-selection bias make direct comparison with historical case reviews inappropriate.

Factors That May Affect Prognosis

Potential prognostic considerations include:

• extent of pericardial disease
• mediastinal involvement
• distant metastases
• involvement of critical cardiovascular structures
• feasibility of meaningful resection
• histology
• cardiovascular health
• general performance status
• ability to receive systemic or multimodality treatment

Pericardial-specific evidence is strongest for disease extent; the independent prognostic effects of histology and treatment selection remain uncertain because available cohorts are very small and retrospective. In the 103-case review, mediastinal or metastatic spread was associated with worse survival, while chemotherapy was associated with longer survival in retrospective analysis.

Because primary pericardial mesothelioma is so rare, the evidence supporting individual prognostic factors is considerably weaker than it is for pleural mesothelioma. Our complete guide to Mesothelioma Prognosis and Survival covers these concepts in more detail.

No online calculator can reliably predict an individual patient’s prognosis.

Why Specialist Care Matters

Primary pericardial mesothelioma sits at the intersection of oncology and cardiovascular medicine.

A multidisciplinary team may include:

• cardiology
• cardio-oncology
• cardiac or thoracic surgery
• medical oncology
• radiation oncology
• cardiac imaging
• pathology
• genetics
• palliative care

Important specialist questions include:

• Did the tumor truly originate in the pericardium?
• Has the pathology been confirmed?
• Is the tumor localized or diffuse?
• Is the myocardium involved?
• Are major vessels involved?
• Is there mediastinal or distant disease?
• Is meaningful surgical removal feasible?
• How should recurrent pericardial fluid be managed?
• Is systemic therapy appropriate?
• Is there a realistic role for radiation?
• Is a clinical trial available?

Because the disease is exceptionally rare, a second opinion can be particularly valuable before major surgery or when the diagnosis remains uncertain. Obtaining a second opinion does not require transferring all future care to another hospital. A specialist center can review pathology, imaging, and treatment plans while some care continues locally.

Questions to Ask Your Medical Team

1. Has my diagnosis been reviewed by a pathologist experienced in mesothelioma?
2. Are you confident that the cancer originated in the pericardium rather than spreading there from another site?
3. What histologic subtype do I have?
4. Is the tumor localized or diffuse?
5. Does imaging show involvement of the myocardium, coronary vessels, or major vessels?
6. Is there mediastinal, lymph-node, or distant disease?
7. Do I have a clinically important pericardial effusion?
8. Is the effusion affecting how my heart fills or pumps?
9. What is the best strategy for managing recurrent fluid?
10. Is meaningful surgical removal possible?
11. What would surgery be intended to achieve in my case?
12. Should platinum-pemetrexed chemotherapy be considered?
13. How much evidence supports the proposed systemic treatment specifically for pericardial mesothelioma?
14. Is immunotherapy reasonable in my situation, and how much of the evidence is extrapolated from pleural mesothelioma?
15. Could radiation therapy have a role?
16. Should I have germline genetic testing and genetic counseling?
17. Are there clinical trials for which I might be eligible?
18. Would review at a center experienced in both mesothelioma and complex pericardial disease be useful?

Frequently Asked Questions

References

1. McGehee E, Gerber DE, Reisch J, Dowell JE. Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases. Clinical Lung Cancer. 2019;20(2):e152–e157. doi:10.1016/j.cllc.2018.11.008.
2. Cao S, Jin S, Cao J, et al. Malignant Pericardial Mesothelioma: A Systematic Review of Current Practice. Herz. 2018;43(1):61–68. doi:10.1007/s00059-016-4522-5.
3. Marinaccio A, Consonni D, Mensi C, et al. Association Between Asbestos Exposure and Pericardial and Tunica Vaginalis Testis Malignant Mesothelioma: A Case-Control Study and Epidemiological Remarks. Scandinavian Journal of Work, Environment & Health. 2020;46(6):609–617. doi:10.5271/sjweh.3895.
4. Alves de Lima A, Carrero MC, Stutzbach PG, et al. Primary Pericardial Mesothelioma: A Rare and Aggressive Malignancy — Case Report and Literature Review. American Journal of Cardiology. 2026;263:22–26. doi:10.1016/j.amjcard.2025.12.008.
5. Nilsson A, Rasmuson T. Primary Pericardial Mesothelioma: Report of a Patient and Literature Review. Case Reports in Oncology. 2009;2(2):125–132. doi:10.1159/000228894.
6. Offin M, De Silva DL, Sauter JL, et al. Multimodality Therapy in Patients With Primary Pericardial Mesothelioma. Journal of Thoracic Oncology. 2022;17(12):1428–1432. doi:10.1016/j.jtho.2022.08.017.
7. Kindler HL, Ismaila N, Bazhenova L, et al. Treatment of Pleural Mesothelioma: ASCO Guideline Update. Journal of Clinical Oncology. 2025;43(8):1006–1038. doi:10.1200/JCO-24-02425. Although the guideline’s target population is pleural mesothelioma, Recommendations 7.1 and 7.6 explicitly address all patients with mesothelioma for germline testing and pretest counseling.
8. Husain AN, Chapel DB, Attanoos R, et al. Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 Update of the Consensus Statement From the International Mesothelioma Interest Group. Archives of Pathology & Laboratory Medicine. 2024;148(11):1251–1271. doi:10.5858/arpa.2023-0304-RA.
9. Schulz-Menger J, Collini V, Gröschel J, et al. 2025 ESC Guidelines for the Management of Myocarditis and Pericarditis. European Heart Journal. 2025;46(40):3952–4041. doi:10.1093/eurheartj/ehaf192.
10. Takeda K, Gereg C, Liu X, et al. Higher Sensitivity of Pericardial Fluid Cytology Than Biopsy in Malignant Effusions With Potential Explanation of False-Negative Cytology: A Multi-Institutional Analysis. Cytopathology. 2025;36(1):31–40. doi:10.1111/cyt.13447.
11. Arponen O, Salo V, Lönnberg A, et al. Primary Pericardial Mesothelioma: A Case Report of a Patient Treated With an Immune Checkpoint Inhibitor as the Second-Line Treatment. Acta Oncologica. 2021;60(5):687–691. doi:10.1080/0284186X.2021.1887515.
12. Gong J, Wu X, Wang J. A Case of Primary Pericardial Mesothelioma Treated With Multimodal Combined Therapy. Frontiers in Cardiovascular Medicine. 2024;11:1433668. doi:10.3389/fcvm.2024.1433668.